Canadian Pacific Kansas City Limited Common Shares vs Merck & Co., Inc. — how do they compare? Canadian Pacific Kansas City Limited Common Shares trades at $83.86 (market cap $73.71B), while Merck & Co., Inc. trades at $142.38 (market cap $352.29B). The key difference: Merck & Co., Inc. is far larger — about 4.8× Canadian Pacific Kansas City Limited Common Shares's market cap, and Merck & Co., Inc. pays the higher dividend (2.38%). Which is the better fit depends on your goals.
| CP | MRK | |
|---|---|---|
Market Cap | $73.71B | $352.29B |
Volume | 2,143,178 | 6,348,796 |
Sector | Industrials | Health |
52-Week High | $96.69 | $156.43 |
52-Week Low | $68.88 | $82.49 |
Enterprise Value | $91.14B | $399.05B |
Dividend Yield | 0.91% | 2.38% |
Typical Hold Time | — | 98 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Canadian Pacific Kansas City operates a freight railway connecting Canada, the United States, and Mexico. The company was formed through the combination of Canadian Pacific and Kansas City Southern.
Read more on CP →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →